Affimed N.V. (AFMD)
After hours:
| Previous Close | 2.0400 |
| Open | 2.0400 |
| Bid | 2.0600 x 27000 |
| Ask | 2.0800 x 2900 |
| Day's Range | 1.9800 - 2.0950 |
| 52 Week Range | 1.4000 - 6.9100 |
| Volume | |
| Avg. Volume | 1,700,519 |
| Market Cap | 312.119M |
| Beta (5Y Monthly) | 2.17 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Motley Fool
Why Shares of Affimed Fell Thursday
Shares of German immuno-oncology company Affimed Therapeutics (NASDAQ: AFMD) were down a little more than 15% on Thursday afternoon. There was no big news from the biotech company, but clinical-stage biotechs are considered riskier stocks than most, and with the markets dropping in general on Thursday, Affimed's shares took a hit. Investors are waiting to hear next month how two clinical trials are faring for one of the company's lead therapies in AFM13.
- Simply Wall St.
Affimed Third Quarter 2022 Earnings: Beats Expectations
Affimed ( NASDAQ:AFMD ) Third Quarter 2022 Results Key Financial Results Revenue: €15.0m (up 69% from 3Q 2021). Net...
- Zacks
Affimed N.V. (AFMD) Reports Q3 Loss, Tops Revenue Estimates
Affimed N.V. (AFMD) delivered earnings and revenue surprises of 42.11% and 96.03%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
